|
AU2015258192A1
|
|
Cancer therapy using CLDN6 target-directed antibodies in vivo
|
|
AU2015242979A1
|
|
Genetic products differentially expressed in tumors and the use thereof
|
|
AU2015205868A1
|
|
Monoclonal antibodies for treatment of cancer
|
|
WO2016165762A1
|
|
Drug conjugates comprising antibodies against claudin 18.2
|
|
WO2016165765A1
|
|
Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
|
|
AU2014208256A1
|
|
Monoclonal antibodies against claudin-18 for treatment of cancer
|
|
EP2958945A1
|
|
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
AU2013260709B2
|
|
Genetic products differentially expressed in tumors and the use thereof
|
|
WO2014146672A1
|
|
Therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
WO2014127785A1
|
|
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
AU2012233044A1
|
|
Genetic products differentially expressed in tumors and the use thereof
|
|
WO2013174403A1
|
|
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
WO2013174404A1
|
|
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
WO2013167153A1
|
|
Antibodies useful in cancer diagnosis
|
|
CN103748112A
|
|
Antibodies for treatment of cancer expressing claudin 6
|
|
AU2012202225A1
|
|
Monoclonal antibodies against claudin-18 for treatment of cancer
|
|
AU2012200098A1
|
|
Identification of surface-associated antigens for tumour diagnosis and therapy
|
|
AU2011256897A1
|
|
Genetic products differentially expressed in tumors and the use thereof
|
|
AU2011218666A1
|
|
Genetic products which are differentially expressed in tumors and use thereof
|
|
NZ628284A
|
|
Antibodies specific for claudin 6 (cldn6)
|
